Shopping Cart
- Remove All
- Your shopping cart is currently empty
PI3K/Akt/CREB activator 1 (AE-18) is a selective inducible nitric oxide synthase (iNOS) inhibitor that crosses the blood-brain barrier, reduces infarct size and restores blood supply deficits after ischemia-reperfusion in rats, and is used in studies of vascular dementia and Parkinson's disease.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $67 | In Stock |
Description | PI3K/Akt/CREB activator 1 (AE-18) is a selective inducible nitric oxide synthase (iNOS) inhibitor that crosses the blood-brain barrier, reduces infarct size and restores blood supply deficits after ischemia-reperfusion in rats, and is used in studies of vascular dementia and Parkinson's disease. |
In vitro | PI3K/Akt/CREB activator 1 (Compound AE-18) (10 and 20 μM; 48 hr treatment) enhances BDNF expression in Neuro-2a cells through activation of the PI3K/Akt/CREB pathway, which promotes the formation of neurites and cell proliferation. Treatment of neurons with 10 and 20 μM PI3K/Akt/CREB activator 1 enhances the differentiation of cultured hippocampal neurons and promotes axonal and dendritic polarity formation through the PI3K/Akt signaling pathway. [1] |
In vivo | In male Sprague-Dawley rats in a chronic cerebral hypoperfusion (CCH) model, gavage of 5 and 10 mg/kg PI3K/Akt/CREB activator 1 promoted the recovery of cerebral blood flow (CBF) after bilateral common carotid artery ligation (BCCAO). PI3K/Akt/CREB activator 1 (5 and 10 mg/kg; by gavage; for 5 consecutive days) attenuated learning and memory impairments in a rat model of CCH, while alleviating hippocampal pathology damage caused by BCCAO. [1] |
Molecular Weight | 381.32 |
Formula | C19H15F4NO3 |
Cas No. | 2708177-73-3 |
Smiles | C([C@H](NC(/C=C/C1=CC=C(C(F)(F)F)C=C1)=O)C(O)=O)C2=CC=C(F)C=C2 |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 200.00 mg/mL (524.49 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.